COMPLEMENT 3 GLOMERULOPATHY (C3G)
Clinical trials for COMPLEMENT 3 GLOMERULOPATHY (C3G) explained in plain language.
Never miss a new study
Get alerted when new COMPLEMENT 3 GLOMERULOPATHY (C3G) trials appear
Sign up with your email to follow new studies for COMPLEMENT 3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for Post-Transplant kidney disease recurrence
Disease control CompletedThis study tested a drug called pegcetacoplan in 13 people whose rare kidney diseases (C3G or IC-MPGN) returned after a kidney transplant. The goal was to see if the drug could reduce signs of disease in the kidney and was safe. Participants received the drug or standard care, an…
Matched conditions: COMPLEMENT 3 GLOMERULOPATHY (C3G)
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 11:07 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, compared to a placebo. Participants received injections twice a week …
Matched conditions: COMPLEMENT 3 GLOMERULOPATHY (C3G)
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC